- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02514824
MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma
This research study is studying a targeted therapy as a possible treatment for merkel cell carcinoma.
- The name of the study intervention involved in this study is: MLN0128.
Study Overview
Detailed Description
This is a phase I/II clinical trial. A phase I clinical trial tests the safety of an investigational intervention and also tries to define the appropriate dose of the investigational intervention to use for further studies. "Investigational" means that the intervention is being studied.
The FDA (the U.S. Food and Drug Administration) has not approved MLN0128 as a treatment for any disease.
MLN0128 may prevent tumor cells from dividing and growing by selectively and potently inhibiting a chemical, mTOR kinase, which regulates cell growth and survival.
Patients with merkel cell carcinoma have been observed to sometimes carry genetic alterations in their tumor cells which may make the cancer more sensitive to inhibition by MLN0128. In this research study,the investigators are studying the usefulness of MLN0128 in merkel cell carcinoma cases.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Dana Farber Cancer Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Metastatic or recurrent MCC confirmed by histology
- Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as > 20 mm with conventional techniques or as > 10 mm with spiral CT scan (see section 10 for the evaluation of measureable disease). Tumors within a previously irradiated field will be designated as "non-target" lesions unless progression is documented
- Age 18 years or older
- ECOG performance status ≤ 2
- Participants must have normal organ and marrow function
Female patients who:
Are postmenopausal for at least 1 year before the screening visit
--- OR
- Are surgically sterile --- OR
- If they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time
Male patients, even if surgically sterilized (ie, status post-vasectomy), who:
- Agree to practice effective barrier contraception during the entire study treatment period and through 90 days after the last dose of study drug, or
- Agree to completely abstain from heterosexual intercourse
- Treatment with strong CYP2C19, CYP3A4, and CYP2C9 inhibitors and/or inducers
- Tissue for correlative studies must be available (paraffinized or frozen)
- Ability to swallow oral medications and maintain an empty stomach state for 2 hours prior to the MLN0128 dose and for 1 hour following administration
- Ability to understand and the willingness to sign a written informed consent
Exclusion Criteria:
- Participants who have had chemotherapy or radiotherapy within 2 weeks prior to entering the study
- The subject has active brain metastases or epidural disease
- Participants who are receiving any other investigational agents within 14 days before the first dose of study drug
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations
- Female patients who are both lactating and breastfeeding or have a positive serum pregnancy test during the screening period or a positive urine pregnancy test on Day 1 before first dose of study drug
- Manifestations of malabsorption due to prior gastrointestinal (GI) surgery, GI disease, or for an unknown reason that may alter the absorption of MLN0128
- Poorly controlled diabetes mellitus
History of any of the following within the last 6 months prior to study entry:
- Ischemic myocardial event
- Ischemic cerebrovascular event
- Requirement for inotropic support (excluding digoxin) or serious (uncontrolled) cardiac arrhythmia
- Placement of a pacemaker for control of rhythm
- New York Heart Association (NYHA) Class III or IV heart failure
- Pulmonary embolism
Significant active cardiovascular or pulmonary disease at the time of study entry, including:
- Uncontrolled high blood pressure
- Pulmonary hypertension
- Uncontrolled asthma
- Significant valvular disease; severe regurgitation or stenosis
- Medically significant (symptomatic) bradycardia
- History of arrhythmia requiring an implantable cardiac defibrillator
- Baseline prolongation of the rate-corrected QT interval (QTc)
- Initiation of treatment with hematopoietic growth factors, transfusions of blood and blood products, or systemic corticosteroids
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose Level 1: MLN01283 3 mg (Phase 1)
Phase 1 dose level 1 participants receive MLN01283 3 mg orally once daily of a 28 day cycle. Participants are treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons. |
Investigational mTOR kinase inhibitor
Other Names:
|
Experimental: Dose Level 2: MLN01283 4 mg (Phase 1)
Phase 1 dose level 2 participants receive MLN01283 4 mg orally once daily of a 28 day cycle. Participants are treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons. |
Investigational mTOR kinase inhibitor
Other Names:
|
Experimental: Dose Level 3: MLN01283 5 mg (Phase 1)
Phase 1 dose level 3 participants receive MLN01283 5 mg orally once daily of a 28 day cycle. Participants are treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons. |
Investigational mTOR kinase inhibitor
Other Names:
|
Experimental: MLN01283 RP2D (Phase 2)
Phase 2 participants receive MLN01283 at the recommended phase 2 dose (RP2D) orally once daily of a 28 day cycle. Participants are treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons. |
Investigational mTOR kinase inhibitor
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
MLN01283 Maximum Tolerated Dose (MTD) [Phase I]
Time Frame: The observation period for DLT evaluation was the first 28 days (cycle 1) of treatment.
|
The MLN01283 MTD is determined by the number of participants who experience a dose limiting toxicity (DLT).
See subsequent primary outcome measure for the DLT definition.
The MTD is defined as the highest dose at which fewer than one-third of patients experience a DLT.
If no DLTs are observed, the MTD is not reached but the highest dose received may be the Recommended Phase II Dose (RP2D).
|
The observation period for DLT evaluation was the first 28 days (cycle 1) of treatment.
|
Dose Limiting Toxicity (DLT) [Phase I]
Time Frame: The observation period for DLT evaluation was the first 28 days (cycle 1) of treatment.
|
A DLT was defined as an adverse event (AE) assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications meets any of the following criteria including but not limited to: grade (G) 4-5 AEs, G3 thrombocytopenia, neutropenia, AST, ALT, serum creatinine or total bilirubin 2 to 3 x upper limit normal (ULN), aymptomatic amylase and/or lipase lasting >7 consecutive days; febrile neutropenia; G3 cardiac, hyperglycemia, mood alteration; G2 pancreatitis; G2 hyperglycemia unresolved within 14 days; G2 mood alteration unresolved in 14 days despite medical treatment; Dose interruption >21 days due to G2 dematologic; one grade level increase neurotoxicity.
|
The observation period for DLT evaluation was the first 28 days (cycle 1) of treatment.
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Virus Diseases
- Infections
- Neoplasms by Histologic Type
- Neoplasms
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- DNA Virus Infections
- Tumor Virus Infections
- Neuroendocrine Tumors
- Polyomavirus Infections
- Carcinoma, Neuroendocrine
- Carcinoma
- Carcinoma, Merkel Cell
Other Study ID Numbers
- 15-223
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Merkel Cell Carcinoma
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Merkel Cell Carcinoma | Metastatic Merkel Cell Carcinoma | Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8 | Pathologic Stage IIIA Cutaneous Merkel... and other conditionsUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Merkel Cell Carcinoma | Refractory Merkel Cell Carcinoma | Locally Advanced Merkel Cell Carcinoma | Unresectable Merkel Cell Carcinoma | Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8United States
-
National Cancer Institute (NCI)CompletedRecurrent Merkel Cell Carcinoma | Stage III Merkel Cell Carcinoma AJCC v7 | Stage IV Merkel Cell Carcinoma AJCC v7 | Stage IIIA Merkel Cell Carcinoma AJCC v7 | Stage IIIB Merkel Cell Carcinoma AJCC v7United States
-
Melanoma and Skin Cancer Trials LimitedRecruitingNeuroendocrine Tumors | Merkel Cell Carcinoma | Merkel Cell Carcinoma, Stage I | Merkel Cell Carcinoma, Stage II | Merkel Cell Carcinoma, Stage III | Carcinoma Neuroendocrine SkinAustralia, New Zealand
-
University of WashingtonEMD SeronoActive, not recruitingStage III Merkel Cell Carcinoma AJCC v8 | Stage IIIB Merkel Cell Carcinoma AJCC v8 | Stage IIIA Merkel Cell Carcinoma AJCC v8United States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRecurrent Merkel Cell Carcinoma | Stage IV Merkel Cell CarcinomaUnited States
-
National Cancer Institute (NCI)SuspendedPathologic Stage I Cutaneous Merkel Cell Carcinoma AJCC v8 | Pathologic Stage II Cutaneous Merkel Cell Carcinoma AJCC v8 | Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8United States
-
ImmunityBio, Inc.UnknownStage IIIB Merkel Cell Carcinoma | Stage IV Merkel Cell CarcinomaUnited States
-
University of WashingtonIncyte CorporationRecruitingMerkel Cell Carcinoma | Clinical Stage IV Merkel Cell Carcinoma AJCC v8 | Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8United States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI); EMD SeronoTerminatedStage IV Merkel Cell Carcinoma AJCC v7 | Merkel Cell Polyomavirus InfectionUnited States
Clinical Trials on MLN0128
-
Millennium Pharmaceuticals, Inc.CompletedWaldenstrom Macroglobulinemia | Refractory Multiple Myeloma | Relapsed Multiple MyelomaUnited States
-
Millennium Pharmaceuticals, Inc.CompletedAdvanced Solid MalignanciesUnited States, Spain
-
Calithera Biosciences, IncCompletedAdvanced Solid TumorsUnited States
-
M.D. Anderson Cancer CenterMillennium Pharmaceuticals, Inc.WithdrawnMalignant Neoplasms of Female Genital Organs | Malignant Neoplasms of Lip Oral Cavity and Pharynx | Malignant Neoplasms of Digestive Organs | Malignant Neoplasms of Male Genital Organs
-
M.D. Anderson Cancer CenterTakedaTerminated
-
National Cancer Institute (NCI)CompletedRefractory Pancreatic Neuroendocrine Carcinoma | Pancreatic Neuroendocrine Tumor G1 | Pancreatic Neuroendocrine Tumor G2United States
-
Kathy MillerMillennium Pharmaceuticals, Inc.; Big Ten Cancer Research ConsortiumTerminatedHCC | Hepatocellular Carcinoma | Liver CancerUnited States
-
University of Colorado, DenverCompletedMetastatic Breast Cancer | Solid TumorsUnited States
-
Memorial Sloan Kettering Cancer CenterMillennium Pharmaceuticals, Inc.CompletedMetastatic Castration-Resistant Prostate CancerUnited States
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Adult Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | Refractory Adult Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | T Acute Lymphoblastic LeukemiaUnited States